Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Andrew W. Roberts, Matthew S. Davids, John M. Pagel, Brad S. Kahl, Soham D. Puvvada, John F. Gerecitano, Thomas J. Kipps, Mary Ann Anderson, Jennifer R. Brown, Lori A. Gressick, Shekman Wong, Martin Dunbar, Ming Zhu, Monali Desai, Elisa Cerri, Sari H. Enschede, Rod Humerickhouse, William G. Wierda, John F. Seymour

New England Journal of Medicine, 2015

The Royal Melbourne Hospital, Walter and Eliza Hall Institute of Medical Research, Victorian Comprehensive Cancer Centre, University of Melbourne, Dana-Farber Cancer Institute, Swedish Medical Center, Washington University in St. Louis, University of Arizona, Cornell University, Memorial Sloan Kettering Cancer Center, University of California, San Diego, AbbVie (United States), The University of Texas MD Anderson Cancer Center, Peter MacCallum Cancer Centre

View Free PDF Publisher Website

Abstract

This research paper explore the methodology and findings associated with New England Journal of Medicine. The study delves into the core aspects of the research field, providing significant data and citation impact. (Full abstract processing is available via the OpenAlex API).

1865

Citations

View on Google Scholar

Targeting BCL2 with Venetoclax in Relapsed Chronic Lymphocytic Leukemia

Abstract

Journal Details

Join JournalsHub

Welcome Back